This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
PTGES2 · Western blot design guide
PTGES2 Western Blot Planning Guide
Plan a PTGES2 Western blot around the catalog-observed 41.9 kDa band, image-backed A06706-2 evidence, HPA controls, and verified protocol records.
Evidence assembled July 2026 · For research use; verify linked source records and product datasheet before use
PTGES2 Western Blot Experimental Design Guide
Expected bands, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | 41.9 kDa | |
| Observed band | Not reported — verify product WB image | |
| Gel | 12-15% | |
| Positive control | Adrenal gland | |
| Negative control | Soft tissue |
Important caveats
Reasons your observed band may differ from the expected size.
| ⓘ | Calculated mass | 41.9 kDa |
| ⓘ | Localization | Golgi apparatus membrane / Cytoplasm, perinuclear region |
| ⓘ | Processing / PTM | Record-dependent |
| ⓘ | Reactivity | Human / Mouse / Rat |
Section 1
Real Curated PTGES2 Western Blot Protocols
Start with the molecular-weight rule, then compare verified publication-derived conditions.
| Sample / lysate | Adrenal gland |
| Gel % | 12-15% |
| Load | 20-30 µg total protein per lane |
| Transfer | Semi-dry, standard transfer |
| Membrane | 0.45 µm PVDF |
| Blocking | 5% non-fat milk or 5% BSA in TBST |
| Primary | A06706-2 at datasheet starting dilution |
| Primary incubation | Overnight at 4 °C with gentle agitation |
| Secondary | Species-matched HRP conjugate at validated dilution |
| Wash | 3 × 5 min in TBST |
| Detection | Chemiluminescent substrate |
| Exposure | Bracket exposures to avoid saturation |
Section 2
What Is the Expected PTGES2 Western Blot Band Size?
Use the product-observed 41.9 kDa band as the primary planning value and retain the UniProt calculated mass as context.
| 41.9 kDa | Matches the authoritative product WB observation. |
| 41.9 kDa calculated | Use as UniProt context, not as a replacement observed band. |
| Unexpected additional signal | Do not assign identity without orthogonal positive/negative controls. |
💡Expected PTGES2 appearancePlan around 41.9 kDa and keep the calculated mass as supporting context.
| Catalog-observed band | 41.9 kDa; use this as the primary experimental expectation. |
| Calculated mass | 41.9 kDa from UniProt Q9H7Z7; retain as context. |
| Gel selection | 12-15%; shared with the recommended protocol and poster. |
| Specificity check | Compare the lead HPA positive and negative controls with A06706-2. |
| Situation | Likely cause | Next action |
|---|---|---|
| 41.9 kDa | Matches the authoritative product WB observation. | Confirm with orthogonal controls and the linked product record. |
| Additional band | May reflect processing, modification, or non-specific signal. | Run a dilution series and compare positive/negative controls. |
| Weak signal | Target abundance or transfer may be limiting. | Verify transfer, increase positive-control abundance, and bracket exposure. |
Experiment evidence
Western blot images showing PTGES2 band
A06706-2 · PTGES2
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for PTGES2 Western blot
🧪Use Adrenal gland as the first positive-control candidate and Soft tissue as the HPA Not detected negative candidate.
Positive control: Adrenal gland (High)
Negative control: Soft tissue (Not detected)
HPA protein score determines control status; other expression data is supporting context only.
HPA tissue expression evidence for PTGES2
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adrenal gland | Reported tissue cells | High | Protein (HPA) | HPA → |
| Kidney | Reported tissue cells | High | Protein (HPA) | HPA → |
| Pancreas | Reported tissue cells | High | Protein (HPA) | HPA → |
| Endometrium | Reported tissue cells | High | Protein (HPA) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Soft tissue | Reported tissue cells | Not detected | Protein (HPA) | HPA → |
Section 3
Advanced PTGES2 Western Blot Tips
Deeper troubleshooting and optimisation questions for PTGES2, answered from its protein features.
Which band should guide the blot?
Use 41.9 kDa, the observation attached to the authoritative A06706-2 WB record.
How should calculated mass be interpreted?
Treat the UniProt calculated mass as context; it does not replace the catalog-observed 41.9 kDa expectation.
Which positive control should I start with?
Start with Adrenal gland, the lead HPA protein-expression candidate.
Which negative control is defensible?
Use Soft tissue as an orthogonal HPA Not detected candidate.
Which gel should I use?
Use 12-15% consistently across the quick facts, protocol table, and poster.
What transfer method to use for PTGES2 Western blot?
Use the transfer method in the recommended protocol and verify transfer before blocking.
How should A06706-2 be started?
Start at the linked datasheet condition and run a three-point primary-antibody dilution test.
Which publication-derived protocols can I compare?
Compare only the supplied target-verified records: PMC10141957, PMC10859596, PMC5080328.
Boster reagents
PTGES2 Western Blot Reagents
Human/Mouse/Rat-reactive PTGES2 Western blot reagents with authoritative product imagery.
Real WB data
Anti-PTGES2/Gbf1 Antibody Picoband®
Cat # A06706-2
Only image-backed, WB-validated Human/Mouse/Rat recommendations from the prepared catalog evidence are shown.
Source: prepared picoband-wb product evidence; each card retains its own SKU, URL, observed band, and authoritative WB image.
References
- UniProt Q9H7Z7
- Human Protein Atlas — PTGES2
- A06706-2 product record
- PMC10141957 — PLPP/CIN-mediated NF2 S10 dephosphorylation distinctly regulates kainate-induced seizure susceptibility and neuronal death through PAK1-NF-κB-COX-2-PTGES2 signaling pathway.
- PMC10859596 — Inhibiting cholesterol de novo synthesis promotes hepatocellular carcinoma progression by upregulating prostaglandin E synthase 2-mediated arachidonic acid metabolism under high fatty acid conditions.
- PMC5080328 — Prostaglandin E2 (PGE2) promotes proliferation and invasion by enhancing SUMO-1 activity via EP4 receptor in endometrial cancer.